Blood test for leftover cancer after prostate surgery in high-risk prostate cancer

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with high-risk prostate cancer who are scheduled for robot-assisted radical prostatectomy (surgery to remove the prostate).

Age

18 years or older

Sex

Men only

Disease stage

High-risk localized prostate cancer (PSA above 20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) on biopsy, or iT3a on multi-parametric MRI), or high-risk locally advanced prostate cancer (any PSA, any Gleason score/ISUP grade, iT3b-4 on MRI, or iN1 on PSMA PET/CT).

Earlier treatment

The person must be scheduled for robot-assisted radical prostatectomy.

Main reasons for not taking part

• Medical reasons that may limit follow-up or blood collection, as judged by the including physician

The registry criteria, word for word

What the trial wants to find out

The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.

The group in the trial

• High-risk localized prostate cancer or high-risk locally advanced prostate cancer

  Included patients will have: 1. High-risk localized prostate cancer, with PSA level \>20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or 2. High-risk locally advanced prostate cancer, having any PSA level, any Gleason score/ISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET/CT imaging).